Answers are grounded in this paper and cite their sources.
Rationale: For advanced osteosarcoma refractory to chemotherapy, our previous phase II trial of advanced osteosarcoma progressing after chemotherapy (Apatinib Plus camrelizumab for unresectable high-grade Osteosarcoma) revealed that although the combination of apatinib and camrelizumab seemed to prolong progression-free survival in comparison to single agent apatinib in treating advanced osteosarcoma, it did not reach the prespecified target of 6-month progression-free survival of 60% or greater. Until last follow-up, 2 durable therapeutic effects were observed. Here, we present these 2 cases with detailed clinical information to gain insights into the characteristics of these clinical beneficiaries. Patient concerns: We present the clinical courses of 2 cases. Case 1 was a 44-year-old male with the primary tumor located at proximal femur. Following routine chemotherapy for osteosarcoma, the patient developed multiple pulmonary metastases and local recurrence. Case 2 was a 14-year-old female with primary tumor located at proximal tibia and fibula. Her disease progressed during chemotherapy after definitive surgery with multiple calcified pulmonary metastases. Diagnosis: High grade osteosarcoma with progression upon routine chemotherapy Interventions: Both the patients were enrolled in the advanced osteosarcoma progressing after chemotherapy trial and were treated with Apatinib 500 mg orally once daily and Camrelizumab 200 mg intravenously administered once every 2 weeks in a 4-week (28 days) cycle. Outcomes: Case 1 showed a partial response for 2 years after enrollment. The dose of apatinib was reduced due to adverse events and eventually stopped. As of February 2020, the lung lesions show a stable response and the patient is disease-free. The residual femoral lesions are planned to be treated by radiation therapy. Case 2 showed stable disease for more than 18 months after the enrollment. She is the only patient from the trial who is still using the drug combination. The last follow-up time was March 1st of 2020. Lessons: These 2 cases suggested osteosarcoma might not always be refractory to anti-PD-1/ programmed death-ligand 1 axial therapy. More prospective trials are needed to determine the biomarkers that may aid in patient selection for this combination. Trial registration: This trial is registered with ClinicalTrials.gov, number NCT03359018.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: